Inside the research

QuidelOrtho Corporation

QDEL Research profile · latest available data

Price overview

$10.94

▲ +0.25 (+2.3%)

52w hi$35.38
52w lo$9.96
Vol1.38M
As of25 Sep 2026

The Verdict

Hold

Our score -0.43

Short-0.33
Medium-0.38
Long-0.71

computed 2026-09-27

Key fundamentals

QuidelOrtho Corporation

Healthcare · Medical Devices

Market cap$750.22M
Enterprise value$3.70B
Forward P/E7.59x
EV / EBITDA7.64x
P / S (ttm)0.28x
Profit margin-39.2%
Return on equity-45.9%
Revenue growth+2.8%
Debt / equity173.28

Layer Breakdown

LayerRawContribution
Fundamental-0.10
Sector+0.08
Technical-0.29
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

United States · www.quidelortho.com

Risk Metrics

Beta vs SPX1.83
Corr SPX0.37
Annual vol79.0%
Annual ret-40.3%
Sharpe-0.51
Max DD-79.1%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-06-23Officer / Director Change, Reg FD Disclosure…read
2026-06-16Shareholder Voteread
2026-05-05Earnings Release, Exhibitsread
2026-04-15Earnings Release, Exhibitsread
2026-03-24Officer / Director Change, Reg FD Disclosure…read
2026-02-13Officer / Director Changeread
2026-02-11Earnings Release, Exhibitsread
2026-02-05Officer / Director Changeread
2025-11-10Reg FD Disclosure, Exhibitsread
2025-11-05Earnings Release, Exhibitsread
2025-08-21Material Agreement, Material Obligation…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-07-01Hanson Bryan MichaelEVP Global Port. Mgmt & MOption exercise5.80K—
2026-07-01Hanson Bryan MichaelEVP Global Port. Mgmt & MWithheld for tax2.10K$38.11K

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders7
Top-5 share99.3%
HHI4,055 (concentrated)

Top Holders

HolderValueShares
Fidelity / FMR LLC$128.98M7.36M
State Street Corp$52.17M2.98M
AQR Capital Management$15.96M911.12K
Millennium Management$12.65M722.48K
Capital Research / Capital World$10.00M570.93K
Citadel Advisors$1.60M91.20K
T. Rowe Price Group$1.80K102.62K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-0710-Qview
2026-08-068-Kview
2026-07-164view
2026-07-153view
2026-07-024view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-294view
2026-06-238-Kview

The Long Run

FY 2022–2025 · 4 years

LineLatestCAGRTrend
Revenue$3.00B+21.7%
Operating income$139.10M-63.8%
Net income-$10.10M-17.7%
Cash from ops$105.20M-49.3%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$10.69$10.95$10.42$10.941.38M
Sep 24$10.35$10.93$10.35$10.691.44M
Sep 23$10.92$11.10$10.32$10.341.11M
Sep 22$10.86$11.15$10.80$10.941.15M
Sep 21$10.78$10.97$10.40$10.861.07M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →